| Secondary |
| Drug Use For Unknown Indication |
32.7% |
| Product Used For Unknown Indication |
22.0% |
| Atrial Fibrillation |
9.4% |
| Arrhythmia |
6.3% |
| Ill-defined Disorder |
3.8% |
| Pulmonary Embolism |
3.1% |
| Urinary Tract Infection |
2.8% |
| Hypertension |
2.2% |
| Phlebitis |
2.2% |
| Cerebrovascular Accident Prophylaxis |
1.9% |
| Hiv Infection |
1.9% |
| Atrial Flutter |
1.7% |
| Thrombosis Prophylaxis |
1.6% |
| Depression |
1.4% |
| Epilepsy |
1.4% |
| Essential Hypertension |
1.4% |
| Cerebrovascular Disorder |
1.3% |
| Hepatitis C |
1.1% |
| Hypothyroidism |
1.1% |
| Deep Vein Thrombosis |
0.9% |
|
| Vomiting |
13.0% |
| International Normalised Ratio Increased |
12.2% |
| Wound Haemorrhage |
10.4% |
| Subdural Haematoma |
8.7% |
| Rectal Haemorrhage |
6.1% |
| Renal Failure |
5.2% |
| Rhabdomyolysis |
5.2% |
| Muscle Haemorrhage |
3.5% |
| Prothrombin Level Decreased |
3.5% |
| Respiratory Distress |
3.5% |
| Subcutaneous Haematoma |
3.5% |
| Tachypnoea |
3.5% |
| Toxic Skin Eruption |
3.5% |
| Drug Rash With Eosinophilia And Systemic Symptoms |
2.6% |
| Lung Disorder |
2.6% |
| Overdose |
2.6% |
| Pneumonitis |
2.6% |
| Purpura |
2.6% |
| Thrombocytopenia |
2.6% |
| Urinary Tract Infection |
2.6% |
|
| Concomitant |
| Product Used For Unknown Indication |
36.0% |
| Drug Use For Unknown Indication |
14.3% |
| Atrial Fibrillation |
7.1% |
| Multiple Myeloma |
5.8% |
| Hypertension |
5.3% |
| Depression |
3.5% |
| Ill-defined Disorder |
3.0% |
| Cerebrovascular Accident Prophylaxis |
2.5% |
| Hepatitis C |
2.5% |
| Pulmonary Hypertension |
2.5% |
| Osteoporosis |
2.3% |
| Type 2 Diabetes Mellitus |
2.3% |
| Dementia Alzheimer's Type |
2.0% |
| Prostatitis |
2.0% |
| Pain |
1.8% |
| Bronchitis |
1.5% |
| Deep Vein Thrombosis |
1.5% |
| Diabetes Mellitus |
1.5% |
| Juvenile Arthritis |
1.5% |
| Pneumonia |
1.5% |
|
| Pulmonary Embolism |
9.0% |
| Somnolence |
9.0% |
| Thrombocytopenia |
8.2% |
| Weight Decreased |
7.4% |
| Syncope |
5.7% |
| Vomiting |
5.7% |
| Cytolytic Hepatitis |
4.9% |
| Toxic Epidermal Necrolysis |
4.9% |
| Toxic Skin Eruption |
4.9% |
| Vertigo |
4.9% |
| International Normalised Ratio Increased |
4.1% |
| Lung Disorder |
4.1% |
| Ventricular Tachycardia |
4.1% |
| Interstitial Lung Disease |
3.3% |
| Malaise |
3.3% |
| Purpura |
3.3% |
| Pyrexia |
3.3% |
| Renal Failure |
3.3% |
| Renal Failure Acute |
3.3% |
| Weight Increased |
3.3% |
|
| Interacting |
| Product Used For Unknown Indication |
43.1% |
| Pain |
13.8% |
| Atrial Fibrillation |
6.0% |
| Pyrexia |
5.2% |
| Drug Use For Unknown Indication |
3.4% |
| Legionella Infection |
3.4% |
| Arrhythmia |
2.6% |
| Headache |
2.6% |
| Nausea |
2.6% |
| Aortic Valve Replacement |
1.7% |
| Asthma |
1.7% |
| C-reactive Protein Increased |
1.7% |
| Depression |
1.7% |
| Epilepsy |
1.7% |
| Leukocytosis |
1.7% |
| Peripheral Ischaemia |
1.7% |
| Sciatica |
1.7% |
| Superior Vena Cava Syndrome |
1.7% |
| Arthralgia |
0.9% |
| Bronchopneumonia |
0.9% |
|
| International Normalised Ratio Increased |
31.0% |
| Muscle Haemorrhage |
24.1% |
| Drug Interaction |
6.9% |
| Melaena |
6.9% |
| Traumatic Haematoma |
6.9% |
| Anaemia |
3.4% |
| Gingival Bleeding |
3.4% |
| Haemorrhage |
3.4% |
| Myalgia |
3.4% |
| Prothrombin Time Prolonged |
3.4% |
| Rectal Haemorrhage |
3.4% |
| Somnolence |
3.4% |
|
